(Total Views: 557)
Posted On: 01/21/2021 10:55:40 AM
Post# of 72440
Re: thefamilyman #68034
Ha I responded to TIAB this AM and my post was removed in record time.
"Whats disgusting and embarrassing is I have never seen a MD use the term "rote" instead of wrote.
Perhaps it was a Freudian slip. Definition of rote:
"mechanical or habitual repetition of something"
The definition describes your posts.
You are trying too hard which brings your motivation into question. The only truth is found in the PR's, not the confabulation of your anxieties.
A review of the PR's will show is a logical progression of basic scientific research where each success is built upon leading to additional study and success until the clinical trial announcement.In vitro testing conclusively demonstrates Brilacidin is one of the most promising therapeutics for Covid 19. This body of work is leading to human clinical trials where Brilacidin will be given to humans sick with Covid 19. It is a remarkable achievement for such a small company
http://www.ipharminc.com/press-release
-2/18 Initial announcement of Brilacidin for Covid 19
-2/24 Material transfer agreements to virology labs
-2/28 Brilacidin sent to Regional Biodefense Labs {RBL)for study
-3/2 Brilacidin PDF outlines scientific rationale for use against Covid19
-3/9 Brilacidin studies planned at RBL
-3/12 Testing to begin 3/16
-4/1 Brilacidin effective against Covid19 in Vero monkey cells
-4/6 Early discussions of human trials
-4/20 Screening of 11,552 compounds shows Brilacidin a leading drug against Covid19 by inhibiting the M-protease
-4/27 Initial research confirms anti Covid properties more research planned
-5/5 PHRI studies announced
-5/19 Brilacidin reduces Covid 75% in preincubtion Vero cell study
-5/26 Brilacidin reduces Covid in human renal cell line; blocks viral cell entry
-6/11 Brilacidin study to include MERS and SARS pan corona virus testing; Grant application application made
-6/17 Brilacidin inhibits Covid 97% in infected Human respiratory cells
-7/7 Brilacidin active against Covid 19 before during and after Covid infects cells
-7/13 Human clinical trial planning/manufacture of Brilacidin announced
-7/20 Brilacidin at low dosage is effective against Covid19; lower than ABSSI dose
-8/4 Brilacidin shown effective against entire Covid life cycle
-8/24 Brilacidin Selectivity index among highest reported
-8/26 Dr Degrado announced as science advisor
-9/15 Brilacidin synergistic with remdesivir;reduces viral load almost 100%
-10/2 Pre IND meeting; Brilacidin human clinical trials
-10/30 RBL preprint article released; Selectivity index 426 one of highest achieved
-11/2 FDA pre IND response received;CRO secured
-11/16 Overseas CTA submitted;Brilacidin viral resistance unlikely
-11/30 New research for Brilacidin as a pancoronavirus treatment
FDA application submitted
-12/21 Brilacidin for phase 2 Covid study approved
"Whats disgusting and embarrassing is I have never seen a MD use the term "rote" instead of wrote.
Perhaps it was a Freudian slip. Definition of rote:
"mechanical or habitual repetition of something"
The definition describes your posts.
You are trying too hard which brings your motivation into question. The only truth is found in the PR's, not the confabulation of your anxieties.
A review of the PR's will show is a logical progression of basic scientific research where each success is built upon leading to additional study and success until the clinical trial announcement.In vitro testing conclusively demonstrates Brilacidin is one of the most promising therapeutics for Covid 19. This body of work is leading to human clinical trials where Brilacidin will be given to humans sick with Covid 19. It is a remarkable achievement for such a small company
http://www.ipharminc.com/press-release
-2/18 Initial announcement of Brilacidin for Covid 19
-2/24 Material transfer agreements to virology labs
-2/28 Brilacidin sent to Regional Biodefense Labs {RBL)for study
-3/2 Brilacidin PDF outlines scientific rationale for use against Covid19
-3/9 Brilacidin studies planned at RBL
-3/12 Testing to begin 3/16
-4/1 Brilacidin effective against Covid19 in Vero monkey cells
-4/6 Early discussions of human trials
-4/20 Screening of 11,552 compounds shows Brilacidin a leading drug against Covid19 by inhibiting the M-protease
-4/27 Initial research confirms anti Covid properties more research planned
-5/5 PHRI studies announced
-5/19 Brilacidin reduces Covid 75% in preincubtion Vero cell study
-5/26 Brilacidin reduces Covid in human renal cell line; blocks viral cell entry
-6/11 Brilacidin study to include MERS and SARS pan corona virus testing; Grant application application made
-6/17 Brilacidin inhibits Covid 97% in infected Human respiratory cells
-7/7 Brilacidin active against Covid 19 before during and after Covid infects cells
-7/13 Human clinical trial planning/manufacture of Brilacidin announced
-7/20 Brilacidin at low dosage is effective against Covid19; lower than ABSSI dose
-8/4 Brilacidin shown effective against entire Covid life cycle
-8/24 Brilacidin Selectivity index among highest reported
-8/26 Dr Degrado announced as science advisor
-9/15 Brilacidin synergistic with remdesivir;reduces viral load almost 100%
-10/2 Pre IND meeting; Brilacidin human clinical trials
-10/30 RBL preprint article released; Selectivity index 426 one of highest achieved
-11/2 FDA pre IND response received;CRO secured
-11/16 Overseas CTA submitted;Brilacidin viral resistance unlikely
-11/30 New research for Brilacidin as a pancoronavirus treatment
FDA application submitted
-12/21 Brilacidin for phase 2 Covid study approved
(9)
(0)Scroll down for more posts ▼
